• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

    4/21/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email

    Company to host conference call at 8:00 AM ET

    Investor Day Scheduled for May 21, 2026

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Twist will also host an Investor Day for analysts and institutional investors on Thursday, May 21, 2026.

    Fiscal 2026 Second Quarter Financial Results Conference Call Details

    The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

    Investor Day to take place May 21, 2026

    Twist will host an Investor Day for analysts and institutional investors on Thursday, May 21, 2026. The event will feature a tour of the company's manufacturing facility, showcase of automation, multiple customer talks, as well as presentations from several Twist senior leaders highlighting the company's strategic initiatives, growth opportunities and roadmap ahead. The webcast of management presentations will begin at 11:00 am PT.

    Investor Day Webcast Details

    The Investor Day will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. The webcast replay will be available for two weeks. Institutional investors and analysts who are interested in attending in person should reach out to Angela Bitting, SVP, Corporate Affairs.

    About Twist Bioscience Corporation

    At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

    We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

    Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

    Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260421395529/en/

    For Investors:

    Angela Bitting

    SVP, Corporate Affairs

    925-202-6211

    [email protected]

    For Media:

    Amanda Houlihan

    Communications Manager

    774-265-5334

    [email protected]

    Get the next $TWST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    11/4/2025$41.00Overweight
    Stephens
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    More analyst ratings

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Twist Bioscience with a new price target

    Stephens initiated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $41.00

    11/4/25 7:44:48 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Twist Bioscience with a new price target

    Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:32:53 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Twist Bioscience with a new price target

    Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

    6/4/24 7:44:10 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

    Company to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations secti

    4/21/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience to Present at Upcoming Investor Conferences

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 in Boston, MA; fireside chat at 1:50 pm Eastern Time Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10 in Miami, FL; fireside chat at 3:00 pm Eastern Time Leerink Global Healthcare Conference on Wednesday, March 11 in Miami, FL; fireside chat at 8:40 am Eastern Time The fireside chats will be webcast

    2/18/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    SEC Filings

    View All

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    4/9/26 3:21:10 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    3/27/26 1:37:00 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    3/20/26 3:40:47 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    View All

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

    1/5/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/5/24 6:07:26 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Financials

    Live finance-specific insights

    View All

    Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

    Company to host conference call at 8:00 AM ET Investor Day Scheduled for May 21, 2026 Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations secti

    4/21/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's

    2/2/26 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Laponis Adam

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    4/16/26 4:05:07 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Laponis Adam

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    4/13/26 4:05:14 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Starovasnik Melissa A.

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    4/3/26 4:00:10 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care